← Back to guidelines
Infectious Disease36 papers

Extrapulmonary pneumocystis jirovecii infection

Last edited: 4/15/2026

Overview

Extrapulmonary Pneumocystis jirovecii infection refers to the occurrence of Pneumocystis jirovecii outside the lungs, primarily affecting immunocompromised individuals 1.

Diagnosis

  • Clinical and radiological features are crucial for initial suspicion 2.
  • Non-invasive tests show promise but vary in sensitivity and specificity; systematic review indicates mixed performance 1.
  • Bronchoalveolar lavage (BAL) is recommended for definitive diagnosis despite delays in treatment initiation 2.
  • Delaying treatment based on awaiting BAL results is discouraged in high-risk patients 2.
  • Management

  • First-line treatment: High-dose trimethoprim/sulfamethoxazole (TMP/SMX) 2.
  • Alternative regimen: Primaquine plus clindamycin for TMP/SMX intolerance 2.
  • Duration: Typically 3 weeks of antimicrobial therapy 2.
  • Secondary prophylaxis: Indicated post-treatment in all patients 2.
  • Respiratory failure: Non-invasive ventilation is not superior to intubation and mechanical ventilation 2.
  • Glucocorticoids: Use individualized based on clinical judgment 2.
  • Special Populations

  • No specific guidance provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts [].
  • Key Recommendations

  • Initiate empirical treatment for suspected Pneumocystis jirovecii pneumonia based on clinical and radiological findings without awaiting BAL results (Evidence: Moderate 2).
  • High-dose trimethoprim/sulfamethoxazole should be the first-line treatment for PCP (Evidence: Strong 2).
  • Consider secondary prophylaxis after completing initial treatment course in all patients (Evidence: Moderate 2).
  • References

    1 Senécal J, Smyth E, Del Corpo O, Hsu JM, Amar-Zifkin A, Bergeron A et al.. Non-invasive diagnosis of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2022. link 2 Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. The Journal of antimicrobial chemotherapy 2016. link

    Original source

    1. [1]
      Non-invasive diagnosis of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis.Senécal J, Smyth E, Del Corpo O, Hsu JM, Amar-Zifkin A, Bergeron A et al. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2022)
    2. [2]
      ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients.Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P The Journal of antimicrobial chemotherapy (2016)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG